Categories: Health

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, pursuant to the offer letters between Lifecore and each employee, and as a material inducement to each employee joining Lifecore.

The RSU awards and stock options were approved by Lifecore’s compensation committee and were granted as inducement equity awards in accordance with Nasdaq Listing Rule 5635(c)(4) under the Inducement Plan.

The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment. The stock options have an exercise price equal to Fair Market Value (as defined in the Inducement Plan) on the grant date and will vest as to one-third of the shares on the first anniversary of the grant date and as to 1/36th of the shares on each monthly grant date thereafter, subject to continued employment. The stock options have a seven-year term. The RSU award and stock options are each governed by an award agreement and the Inducement Plan.

About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.



GlobeNews Wire

Recent Posts

Cognex Launches In-Sight Vision Controller Powered by NVIDIA

Advanced AI Vision Controller delivers the modularity required to solve demanding, compute-intensive manufacturing applications without…

3 hours ago

Notabene launches Revert to solve crypto’s biggest gap: what happens after a transaction settles

New infrastructure lets institutions safely control, authorize, and track returns of settled crypto transactions, a…

3 hours ago

Centrical Receives Frost & Sullivan’s 2026 Global Transformational Innovation Leadership Recognition for Excellence in Performance Intelligence

Recognized for advancing performance intelligence through transformational innovation that enhances frontline productivity, engagement, and business…

3 hours ago

Verosoft Partner PASI Expands Microsoft Dynamics 365 Business Central into Enterprise Energy and Mining with TAG Mobi EAM

From Mid-Market to Enterprise: How One Partner Scaled Business Central to 2,000+ Users in Energy…

3 hours ago

Milan Design Week 2026: Haier and Fisher & Paykel double down on premium global brand power, pushing boundaries to empower better living

MILAN, April 28, 2026 /PRNewswire/ -- Haier Group (Haier) has successfully concluded its exhibition at…

3 hours ago

CATL and HyperStrong Sign the World’s Largest Sodium-Ion Energy Storage Cooperation Agreement

NINGDE, China, April 28, 2026 /PRNewswire/ -- On April 27, CATL and HyperStrong signed a strategic…

3 hours ago